plerixafor has been researched along with mocetinostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Jin, XX; Liu, J; Lu, H; Lu, YK; Shen, YZ; Wang, FY; Wang, ZK; Xia, XM; Xu, WA | 1 |
2 other study(ies) available for plerixafor and mocetinostat
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
CXCR4 antagonist AMD3100 attenuates colonic damage in mice with experimental colitis.
Topics: Animals; Apoptosis; Benzylamines; Cell Movement; Colitis; Colon; Cyclams; Cytokines; Dextran Sulfate; Female; Heterocyclic Compounds; In Vitro Techniques; Inflammation Mediators; Leukocytes, Mononuclear; Mice; Mice, Inbred BALB C; Permeability; Peroxidase; Receptors, CXCR4 | 2010 |